April 12th, 2024
CT and 129Xe MRI provide complementary lung structure-function information that can be exploited for regional analysis using image registration. Here, we provide a protocol that builds from the existing literature for 129Xe MR to CT image registration using open-source platforms.
To begin, open images followed by masks in the desired image visualization software to verify that the image and mask orientation match for all CT, Proton, and Xenon files. Then, save the image DICOMS and single label masks as NIfTI files in the same folder as the reg. py file.
For CT Xenon MRI registration, open the reg. py file in the desired Python computing environment setup. If using a virtual environment, set the number of central processing units, number of threads, and RAM as desired or as available in the computing environment.
Next, set the desired transformation and interpolation, followed by the fixed and moving image. Run reg. py in the Python computing environment.
Once the registration is complete, proceed for evaluation. Keeping the ct. nii image as the base image, open ventilation warp.nii.
gz as another image and overlay it on the CT image with the desired color map. Review the overlap of the xenon MR image with the CT image in all image planes to evaluate the visual alignment of landmarks such as the carina and lung boundaries. Registration results showed good alignment of all lung boundaries for the healthy participant.
In the three participants with chronic obstructive pulmonary disease, there was good alignment of lung boundaries were available ranging from diffuse ventilation abnormalities, upper lobe ventilation abnormalities with absent apical lung boundaries and lower lobe ventilation abnormalities with absent diaphragmatic lung boundaries.
This article presents a protocol for registering 129 Xe MRI with CT images to enhance lung structure-function analysis. The method utilizes open-source platforms for image registration, facilitating regional analysis.
Integrating hyperpolarized 129Xe MRI with CT imaging enables comprehensive evaluation of lung structure and function, supporting advanced target validation and mechanistic de-risking in respiratory drug discovery. This multi-modal approach enhances predictive confidence at key inflection points in pulmonary R&D pipelines, facilitating risk-adjusted portfolio decisions for novel therapeutics targeting lung disease. The method's quantitative and regional outputs position it as a strategic asset for translational research and preclinical model development.
This multi-modal imaging protocol bridges early discovery, lead identification, and preclinical validation in respiratory R&D workflows.